Morgan Stanley Adjusts AbbVie Price Target to $211 From $196
AbbVie Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $200
J.P. Morgan Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $210
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $200
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management
Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)